Webinar Objectives: 

• Trombocitopenia fetal/neonatal aloinmune: ¿qué?, ¿cuándo?,¿cómo? y ¿por qué?

Speakers: MARÍA DEL MAR LUIS // Centro de Transfusión de la Comunidad Valenciana. Responsable del laboratorio de Inmunología Leucoplaquetar y corresponsable del laboratorio de Inmunohematología de la serie roja - Spain

Webinar Objectives: 

• Seguimiento y tratamiento de gestantes sensibilizadas

Speakers: Aurora Viejo // Hospital Universitario La Paz. Jefe de Sección de Hematología-Hemoterapia - Spain

Webinar Objectives: 

• Inmunohematología de los grupos sanguíneos en el embarazo

Speakers: JORGE MONGE, Responsable del Laboratorio de Inmunohematología. Centro Vasco de Transfusión y Tejidos Humanos (Osakidetza) - Spain

Target:

• The management of anti-e antibodies in patients with sickle cell disease is discussed, focusing on their classification as autoantibodies or alloantibodies and on the transfusion implications, highlighting the need to combine serology, molecular genetics and personalized transfusion strategies to improve safety and efficacy in these patients.

SpeakerLynsi Rahorst, MHPE, MLS(ASCP)^SBBCM

Objective:

• It analyzes the progress and challenges of voluntary blood donation in Latin America, highlighting the evolution of voluntary donation (VD), and emphasizes the importance of collaboration between governments, health services and communities to move towards sustainable and equitable donation systems.

Speaker: Marcela García-Castro

Objective:

• The procedures and tools used in the identification of irregular antibodies in immunohematology, an essential process to ensure safe and effective transfusions, are described. The comprehensive approach combines traditional techniques with advanced technologies to identify irregular antibodies and improve transfusion safety.

Speaker: Rocío Castillo Trigueros

Objective:

• The ABO blood group is described as a population marker in Latin America, exploring its genetic, historical and evolutionary importance.

Speaker: Dr. Héctor A. Baptista González

Objective:

• We analyze the interferences caused by treatments with monoclonal antibodies (MABs) in immunohematology studies, focusing on two specific therapies: anti-CD38 and anti-CD47. MAB therapies represent significant advances in oncology and pose technical challenges in immunohematology that can be addressed by specialized strategies.

Speaker: Fernando Martinez, MD, MScPH

Objective:

• The importance of ABO antibody titer in universal donors is discussed, especially in the context of platelet transfusions by apheresis.
• The risks associated with transfusion of plasma hemocomponents with high titers of anti-A and anti-B antibodies, such as hemolytic transfusion reactions, especially in vulnerable patients, are highlighted.
• The need to improve hemovigilance and transfusion protocols to ensure patient safety is emphasized.

Speaker: Lissett Aguilar Ocaña

Objective:

• The importance of knowing the blood groups present in the populations served to improve transfusion safety and reduce alloimmunization is emphasized.
• It is emphasized that blood groups are highly polymorphic and that antigenic frequencies vary among ethnicities and populations, especially in Latin America due to its genetic diversity and miscegenation.
• Having a thorough knowledge of blood group frequencies and variations is essential to ensure safe and effective care in transfusion medicine.

Speaker: María Antonieta Núñez A., PhD, MSc

Objective:

• A strategy is described for the creation of a National Registry of Donors with Rare Phenotypes in Mexico, focused on their usefulness in transfusion medicine.
• It highlights the importance of identifying and registering donors with rare blood groups due to their relevance in critical clinical cases, such as emergency transfusions and hemolytic diseases.
• It includes statistics on the frequency of blood phenotypes in the Mexican population and clinical cases that illustrate the need for these registries. It also mentions international collaborations and standards, such as those of the International Rare Donor Panel.

Speaker: Dr. Héctor Baptista

Objective:

• To understand the structure and function of platelets. Review the diagnoses that cause thrombocytopenia. To describe the methods used for the detection and identification of platelet antibodies.

Speaker: Marisela G. Marchán, MSc

Objective:

• Use of serological and molecular techniques to resolve ABO typing discrepancies, specifically in blood donors. It is explained how molecular assays contribute to the resolution of discrepancies and are essential to detect weak ABO subgroups that are not detected by routine serology. Molecular typing is crucial to avoid typing errors and ensure the safety of blood products.

Speaker: Lynsi Rahorst, MHPE, MLS(ASCP)SBBCM

Objective:

• To describe the interferences of monoclonal treatments, specifically anti-CD47 antibodies, in immunohematologic studies.
• Anti-CD47 therapy is associated with pan-reactivity in all phases of antibody screening.
• Management strategies for patients such as performing genotyping or phenotyping studies prior to initiating treatment and providing antigen specific antigen negative units such as D, Kell, Jka are discussed.

Speaker: Fernando Martinez, MD, MScPH

Objective:

• To address general concepts in immunohematology, highlighting advances and relevant cases. Included are the use of molecular biology, enhanced hemovigilance, pathogen inactivation, and gene therapy.
• The importance of transfusion compatibility and a multidisciplinary approach to prevent complications is highlighted.

Speaker: Baldomero Castro, MSc.

Objectives: The implementation of the Type and Screen (TAS) protocol in the blood bank of an emergency center in Lima, Peru, is analyzed, highlighting its usefulness for detecting irregular antibodies (Ac) in safe transfusions. The main points are: The Type and Screen Protocol is a method that combines blood typing (ABO/RhD) with irregular antibody screening to predict compatibility before transfusion in a prospective study between 2016 and 2022, where several types of antibodies were detected, the most common being Anti-E, Anti-Dia and autoantibodies. Solid-phase Capture (Immucor) technology was key to identifying these antibodies. Lissette Fernandez

Objective: To review genomic concepts of erythrocyte antigens. The use of immunohematology when patients have been recently transfused, when patients have some antibody to a high or low frequency antigen but no commercial antibody is available, for the management of patients receiving monoclonal therapies, and in prenatal testing to predict hemolytic disease of the newborn. It focuses on the identification of donors with rare blood.

Speaker: Celina Montemayor MD, PhD

Objectives: The importance of titration of natural anti-A and anti-B antibodies in platelet donors is described, highlighting their relevance in reducing post-transfusion hemolytic reactions.

Orador: Lic. Gisel Aguilar Ocaña

Objective: The management of patients refractory to platelet transfusions is addressed, highlighting key concepts, etiology and therapeutic strategies. An example of management in a patient with acute myeloid leukemia refractory to transfusions due to anti-HLA antibodies is illustrated, highlighting the importance of specific tests and personalized transfusions. Correct identification of the cause and personalized management are essential to improve outcomes in refractory patients and the need for specific protocols and adequate resources to address this complex condition is emphasized.

Speaker: Mayrin Correa Medina, MD, Ph.D.

Objective: Key concepts, etiology and therapeutic strategies for the management of patients refractory to platelet transfusions are highlighted. An example of management in a patient with acute myeloid leukemia refractory to transfusions due to anti-HLA antibodies is illustrated, highlighting the importance of specific tests and personalized transfusions. The need for specific protocols and adequate resources to address this complex condition is emphasized. Correct identification of the cause and personalized management are essential to improve outcomes in refractory patients.

Speaker: Fernando Martinez

Objectives: The paper addresses hemolytic disease of the newborn (HDNB) caused by maternal alloimmunization, exploring various clinical, serological and epidemiological aspects. The importance of population genetics and health systems in the management of this neonatal disease is highlighted. EHRN is preventable and treatable through early diagnosis, proper management of blood incompatibility and immunization programs.

Speaker: Dr. Hector Baptista Gonzalez, MD

Objectives: To recognize the serologic presentations of Autoimmune Hemolytic Anemia (AHA). To understand the limitations of abbreviated diagnostic assays. Differentiate cold autoantibody reactivity. The study underlines the importance of detailed testing to correctly characterize autoantibodies and properly manage the condition.

Speaker: Lauro E. Guerra, Jr. MLS(ASCP)SBBCM

网络研讨会的目标：

Describe las las discrepancias y subgrupos en el sistema sanguíneo ABO, diferenciando entre：ABO 差异（Discrepancias ABO）是指直接和反向聚合试验之间存在不一致，或过去和现在的结果之间存在不一致。ABO亚群，代表ABO系统的变体，红细胞中抗原性降低。目前有实例表明，抗 A1 等抗原与预期不符，导致了严重的输血反应，这说明了精确鉴定和适当处理的重要性。临床意义：为确保患者的安全，需要强有力的方案和先进的工具。

主讲人巴尔多梅罗-卡斯特罗博士

Webinar Objetivos:

Describir la importancia de los donantes de reactivos en la fabricación de reactivos de glóbulos rojos utilizados para pruebas serológicas en laboratorios y bancos de sangre. Explica cómo estos donantes, seleccionados por su fenotipo específico, garantizan la disponibilidad de unidades necesarias para detectar anticuerpos y tipificar sangre de manera precisa. Se aborda los desafíos como la competencia con necesidades transfusionales y requisitos regulatorios internacionales, además de destacar configuraciones como las pruebas Capture^® para detección de anticuerpos. También subraya que los donantes de reactivos permiten estabilidad en la producción y evitan retrasos en el suministro de productos esenciales.

Orador: Germán Núñez, MBA

Webinar Objetivo:

Describir las causas y aplicaciones de la prueba de antiglobulina directa (Coombs directo), destacando su relevancia en diagnósticos como anemia hemolítica autoinmune, reacciones transfusionales y enfermedad hemolítica del recién nacido. Incluye ejemplos prácticos para analizar casos, como discrepancias ABO madre-bebé, y destaca técnicas como la elución para identificar anticuerpos específicos adheridos a glóbulos rojos.

Orador: Nancy Benitez, MHS(ASCP) SBB

Webinar Objectivo:

El uso de la genotipificación como herramienta para resolver casos complejos de inmunohematología. Incluye estudios de caso, como uno de un paciente con anemia de células falciformes que presentó dificultad respiratoria y múltiples complicaciones transfusionales. Se detalla el análisis de genotipos para identificar anticuerpos y antígenos relevantes, así como estrategias específicas como el uso de células seleccionadas y técnicas avanzadas para confirmar la especificidad de los anticuerpos y optimizar las transfusiones.

Oradora: Dra. Paula A. Gaviria García

Objetivos del seminario web:

• Se discutira y revisara como resolver casos complejos e intermedios de aloanticuerpos contra células rojas y plaquetas usando serologia y metodos moleculares,
• interferencia de tratamientos monoclonales en immunohematologia ,
• donantes raros y poco comunes

Oradora:  Nancy Benitez;  Claribel Resto; MHSc, MT (ASCP) SBB CM   Baldomero Castro, MD   Lynsi Rahorst, MHPE, MLS(ASCP)SBB Dr.Fernando Martinez, MD, MScP; Section Head and Medical Director Anderson Cancer Center.   Dr. Hector Baptista MD   Marisela Marchan, MSTM , MT (ASCP)SBB

Objetivos del seminario web:

Este seminario está dirigido a profesionales de transfusión, equipos de laboratorio de transfusión y consultores de transfusión con ánimo de comprender mejor las necesidades de este grupo especial de pacientes, los recién nacidos.

Oradora: Martha Sola-Visner. MD.

Objetivos del seminario web:

• Definir resultados de laboratorio de coagulación normales y anormales.
• Correlacionar resultados de laboratorio con signos y síntomas clínicos comunes en el paciente.
• Discriminar resultados de laboratorio de plaquetas normales y anormales.
• Aplicar resultados de coagulación y hematología en estudios de casos centrándose en la provisión de transfusión de hemoderivados o intervención médica.

Oradora: Jayanna Slayten, MS, MT(ASCP)SBB^CM

Objetivos del seminario web:

• Gestión de listas de trabajo
• Gestión de resultados
• Gestión de informes
• Panel de identificación | Módulo
• Gestión de archivos

Oradora: Gianni Giuffrè

Objetivos del seminario web:

•  el desarrollo de la inmunohematología hasta los avances tecnológicos e investigació
• "genómica" y descubrimiento continuo de grupos sanguíneos

Oradora: Dr. Lilian Castilho

Objetivos del seminario web: 

• Definición Antígenos de Baja Frequencia (ABF)
• ¿Porqué estudiar los anticuerpos contra ABF?
• Dificultades en el estudio de ABF

Oradora: Dra. María Antonieta Nuñez

Objetivos del seminario web: 

• Antígenos del Sistema Rh
• La minoría de los antígenos Rh están codificados por el gen RHD
• Variantes RHD
• Genotipificación RHD

Oradora: Dra. Lilian Castilio

Objetivos del seminario web: 

• Genotipificación y su Aplicación en la Medicina Transfusional

Oradora: Maria Antonieta Nunez PhD